What's Happening?
Researchers at the University of Vermont, in collaboration with RS Oncology, have discovered a promising new treatment strategy for mesothelioma, a rare and aggressive cancer. The study, published in Nature Communications, reveals that blocking the enzyme
peroxiredoxin 3 (PRX3) in cancer cells can lead to their death. This approach contrasts with previous methods that aimed to protect cancer cells from oxidative damage. The research team, led by Victoria Gibson and Brian Cunniff, found that inhibiting PRX3 causes harmful molecules to accumulate in cancer cells, ultimately leading to cell death. A phase one clinical trial showed that the experimental drug stopped disease progression in 67% of patients with relapsed mesothelioma. The treatment was well tolerated, and patients survived longer than those receiving standard therapies.
Why It's Important?
This development is significant as mesothelioma is a disease with limited treatment options and a poor prognosis. The discovery of a new vulnerability in mesothelioma cells could lead to more effective treatments, potentially improving survival rates for patients. The approach of targeting PRX3 may also be applicable to other types of cancer, broadening the impact of this research. Additionally, the study highlights the potential of using existing compounds, like thiostrepton, in new ways to combat cancer. This could accelerate the development of new therapies and reduce the time and cost associated with bringing them to market.
What's Next?
The research team plans to present their phase two trial results at a global oncology meeting later this year. They are also working on developing second-generation PRX3 inhibitors that are more soluble and could be administered orally. This would simplify treatment and potentially expand its application to other cancers. Further studies are needed to confirm the efficacy and safety of this approach in larger patient populations. The researchers are also exploring the drug's potential immunomodulatory effects, which could enhance its ability to combat cancer.
